Patient Preference for Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam or Topical Suspension vs. Latest Topical Treatment in the PSO-INSIGHTFUL Study. J of Skin [Internet]. 2018 Feb. 23 [cited 2026 May 2];2(S1):S10. Available from: https://skin.dermsquared.com/skin/article/view/279